Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This will be a Phase 1b, first in human, open-label, dose escalation and expansion study of
MT-5111 (a recombinant fusion protein) given as monotherapy in subjects with HER2-positive
solid tumors
Phase
Phase 1
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Enrollment Eligibility
Inclusion Criteria:
1. Histologically confirmed, unresectable, locally advanced or metastatic solid cancers:
- Part A (Dose-Escalation): All HER2-positive solid cancers are eligible
- Part B (Dose-Expansion): Any type of HER2-positive solid cancer, including breast
cancer, and gastric or gastroesophageal adenocarcinomas (GEA).
2. HER2-positive in the latest tumor sample tested for HER2 (testing to be done on a
metastatic lesion in cases of metastatic cancers).
3. Relapsed or refractory to or intolerant of existing therapy(ies)
4. At least 1 measurable or evaluable lesion according to RECIST 1.1 (Subjects with
evaluable disease only may be included in the dose escalation phase)
5. ECOG performance score of ≤ 1
6. Adequate Bone marrow function as determined by:
- Absolute neutrophil count (ANC) ≥ 1,000/mm3
- Platelet count ≥ 75,000 mm³ and
- Hemoglobin ≥ 8.0 g/dL
- Red blood cell transfusion within 2 weeks of study treatment start is allowed if
hemoglobin levels remain stable
7. Kidney function:
- Creatinine clearance (CLcr) ≥ 50 mL/min either measured or estimated using the
Cockcroft-Gault formula
8. Cardiac Function:
- Left ventricular ejection fraction (LVEF) ≥ 55% on the echocardiogram (ECHO)
assessment (preferred), or multigated acquisition (MUGA) scan, and QTcF ≤ 480 ms
for women and QTcF ≤ 450 ms for men [average from three QTcF values on the
triplicate 12-lead electrocardiogram (ECG)] at baseline
9. Hepatic function:
- Total bilirubin ≤ 1.5 x ULN, or ≤ 3 x ULN for subjects with Gilbert's Syndrome
and
- AST ≤ 3 x ULN (or ≤ 5 x ULN if liver metastasis) and ALT ≤ 3 x ULN (or ≤ 5 x ULN
if liver metastasis)
Exclusion Criteria:
1. History or current evidence of another tumor that is histologically distinct from the
tumor under study
2. Current evidence of new or growing CNS metastases during screening
- Subjects with known CNS metastases will be eligible if they meet protocol
specified criteria
3. Evidence of CTCAE Grade >1 toxicity before the start of treatment, except for hair
loss and those Grade 2 toxicities listed as permitted in other eligibility criteria
4. History or evidence of significant cardiovascular disease
5. Current evidence of active, uncontrolled hepatitis B virus, hepatitis C virus, human
immunodeficiency virus (HIV) (evidenced by detectable viral load by PCR) or acquired
immunodeficiency syndrome (AIDS) related illness
6. Current evidence of ≥ grade 2 underlying pulmonary disease
7. Certain exclusionary prior treatments